NXTC
NextCure·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NXTC
Nextcure, Inc.
A clinical-stage biopharmaceutical company that developing immunomedicines to treat cancer and other immune-related diseases
9000 Virginia Manor Road, Suite 200, Beltsville, Maryland 20705
--
NextCure, Inc., incorporated in Delaware in September 2015, is headquartered in Beltsville, Maryland. The company is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel first-in-class immune drugs to treat cancer and other immune-related diseases by restoring normal immune function. Through its proprietary functional, integrated, NextCure Discovery (" FIND-IO ") platform in immuno-oncology, the Company studies a variety of immune cells to discover and understand the targets and structural components of immune cells and their functional effects to develop immunohistochemistry.
Company Financials
EPS
NXTC has released its 2025 Q3 earnings. EPS was reported at -3.22, versus the expected -3.98, beating expectations. The chart below visualizes how NXTC has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
